CD123: The α-Subunit of IL-3 Receptor Is an Emerging Target in Hematologic Malignancies {#S0001}
=======================================================================================

CD123 is the α-subunit of interleukin (IL)-3 receptor. This receptor belongs to the Common Beta (β~C~) cytokine receptor subfamily with IL-5 and Granulocyte-Macrophage Colony Stimulating Factor receptors. All these membrane receptors are expressed at the surface of myeloid progenitors and play a key role in the regulation of hematopoiesis and inflammatory response. CD123 is expressed on the majority of CD34+ hematopoietic progenitors, but its expression is sustained only in the monocytic and granulocytic lineages. CD123 can be found at the surface of non-classical monocytes, but not granulocytes. It is involved in the proliferation and differentiation of myeloid progenitors, notably through the activation of the JAK/STAT pathway after the reception of IL-3. The expression of CD123 is also found in hematologic malignancies, especially myeloid neoplasms such as acute myeloid leukemia (AML), hairy cell leukemia and blastic plasmacytoid dendritic cell neoplasm (BPDCN).[@CIT0001] Its expression on islands of clonally related plasmacytoid dendritic cells (pDC) in the bone marrow of 20% of chronic myelomonocytic leukemia patients is correlated to an increased risk of AML transformation.[@CIT0002] CD123 was first reported to be a potential target in hematologic disease by Jordan and colleagues in 2000. They demonstrated that the interleukin-3 receptor alpha chain is expressed in CD34+/CD38- leukemic stem cells in AML, whereas it is absent at the surface of normal bone marrow-derived CD34+/CD38- cells.[@CIT0003] Moreover, a high expression level of CD123 has been shown to be involved in enhanced proliferation and poorer outcomes in several hematologic neoplasms.[@CIT0004] Therefore, CD123 is one of the major therapeutic targets in the current development of new therapies in myeloid malignancies.[@CIT0005],[@CIT0006]

Tagraxofusp: Poisoning Tumoral Cells Through CD123 Expression {#S0002}
=============================================================

Tagraxofusp (or SL-401) is a recombinant protein which consists of the diphtheria toxin (DT) without its C-terminal binding domain fused to interleukin-3 (IL-3). This last part of the protein binds to CD123 at the surface of tumor cells. As a result, diphtheria toxin is internalized inside the CD123 expressing tumor cells. It impairs protein synthesis and triggers cell death, notably by Elongation Factor 2 (EF2) inhibition.[@CIT0007]

Tagraxofusp is currently the only novel therapy to receive FDA approval for the treatment of BPDCN in adult and pediatric patients 2 years and older.[@CIT0008] The product received EMA orphan medicinal product designation in February 2019. Targeting CD123 in the treatment of BPDCN is particularly relevant since BPDCN is characterized by a constant overexpression of CD123 on the surface of tumor cells.[@CIT0009] It provided the rationale to investigate the efficacy of tagraxofusp in BPDCN.

BPDCN: A Rare and Highly Refractory Hematologic Malignancy {#S0003}
==========================================================

Clinical Characteristics and Diagnosis {#S0003-S2001}
--------------------------------------

According to the World Health Organization (WHO) 2008 guidelines, BPDCN was classified in the acute myeloid leukemia (AML)/related family of neoplasms. However, following the discovery that it may originate from type 2 dendritic cells (plasmacytoid), classification under WHO 2016 guidelines placed BPDCN in its own category among myeloid malignancies.[@CIT0010]

BPDCN is a rare and aggressive myeloid malignancy with poor outcomes. It mainly affects patients over 60 years of age. Skin is the organ most frequently involved, but BPDCN can also spread to bone marrow, lymph nodes and the central nervous system (CNS). Rapid and aggressive progression to the terminal leukemic phase is common.[@CIT0011]

The diagnosis is based on the identification of clonal cells derived from precursors of plasmacytoid dendritic cells in a sample of an involved organ. Tumor cells must express at least four of five pDCs-specific markers (CD4, CD56, CD123, TCL1A and BDCA-2/CD303, as well as TCF4), and without expressing myeloid, T-cell, or B-cell lineage markers.[@CIT0012] Based on the phenotype, BPDCN is further classified accordingly to maturation status as immature (CD34+), intermediate (CD117+ but CD34-) or mature (CD34- and CD117-). Intermediate and mature BPDCN are preferentially diagnosed from skin and nodal biopsies and immature BPDCN from bone marrow aspiration, but this classification does not provide any prognostic information.[@CIT0013] For minimal residual disease assessment purposes, an immunophenotypic characterization of reactive versus blastic PDC has been published which will undoubtedly help with diagnosis in bone marrow.[@CIT0014]

Cytogenetic features include frequent loss of genetic material such as deletions (del5q31, del9p21.3, del13q13, del7p12, del12p), balanced chromosomal translocations, which are uncommon and not specific to the disorder with the notable exception of t(6;8), involving SUPT3H and MYC loci. The landscape of adult BPDCN genomic alterations is dominated by TET2, ASXL1, NRAS, IKZF1 and NPM1 mutations.

Primary BPDCN is more common (80--90%), but in 10--20% of the cases it develops in the context of hematologic malignancies, with molecular evidence of shared clonal origin in some case reports. Even rarer are cases that occur after chemotherapy for solid tumor or lymphoma. Moreover, myeloid neoplasms may present with associated mature pDC proliferation or a spectrum of pDC differentiation, but these entities are different from BPDCN.[@CIT0015]

Outcome and Response to Conventional Treatments {#S0003-S2002}
-----------------------------------------------

Today, patients are still usually treated with ALL/lymphoma-type or AML-type chemotherapy, and there is no approved standard treatment. With these treatments, overall survival barely exceeds 18 months, in spite of the achievement of an initial complete remission in more than half of the patients.[@CIT0016] Relapse is common, quick, and often lethal.

Prognostic factors of response to these therapies are mostly unknown, however a retrospective study has identified age \> 60 years, abnormal karyotype and terminal deoxynucleotidyltransferase (TdT) negativity in BPDCN cells at diagnosis as a factor of poorer outcomes.[@CIT0017]

Autologous and allogeneic hematopoietic stem cell transplantations (HSCT) have been tried in this condition. They seem to improve overall survival in some cases, but only a few patients are eligible for this type of treatment due to the frequency of an advanced age and a rapidly progressing disease. Moreover, the real efficacy of HSCT in BPDCN cannot be precisely indicated because there are few reports and they include only small groups of patients.[@CIT0018] However, allogeneic stem cell transplantation seems to be a relevant therapeutic option if feasible in first complete remission.[@CIT0019]

Need for Novel Approaches: Emerging Targeted Therapies {#S0003-S2003}
------------------------------------------------------

Therefore, there is a great need for novel therapies in BPDCN. In fact, drugs with a suitable toxicity profile for frail or elderly patients and which significantly improve survival in terms of the quality of life of patients are required.

BPDCN are CD4+CD56+ neoplasms defined by the lack of other cancer-specific cell surface markers, which emphasizes the difficulties finding an adequate target for a therapeutic strategy. CD38 is not always present at the cell surface (unlike reactive pDC). Therefore, CD123 is the most reliable marker to develop antibody-based therapies, such as monoclonal antibodies, antibody drug conjugates, dual affinity re-targeted agents or bispecific antibodies, or even chimeric antigen receptor T-cells.

Based on cytogenetic and molecular features of the disease, some potential therapeutic targets are emerging in BPDCN, among which are NF-kB pathway inhibitors (most often indirect inhibitors such as proteasome inhibitors, for example, bortezomib), DNA hypomethylating agents (5-azacytidine), BCL-2 inhibitors (venetoclax), bromodomain (BRD4) inhibitors, and folate metabolism inhibitors (pralatrexate).[@CIT0020] The development of precision medicine-driven combinations will be the only successful method to transform the prognosis of this disease.[@CIT0021],[@CIT0022] In this regard, recent evidence suggesting that azacytidine might increase BPDCN sensitivity to tagraxofusp through the restoration of the diphthamide synthesis pathway paves the way for conducting a clinical trial in myeloid malignancies.[@CIT0023]

Results of Tagraxofusp in the Treatment of BPDCN {#S0004}
================================================

Pharmacokinetics and Pharmacodynamics {#S0004-S2001}
-------------------------------------

Tagraxofusp is administered intravenously, in a 15-minute infusion once daily for 5 days every three weeks. The area under the curve (AUC) for plasma concentration over time is 231 hr mcg/l and Cmax is 162 mcg/l. The mean volume of distribution is 5.1 L. Mean terminal half-life is 0.7 hours. As a fusion protein with a molecular weight of 58 kDa, tagraxofusp is expected to be eliminated via degradation and renal pathways.[@CIT0024]

Efficacy {#S0004-S2002}
--------

Viability assays in vitro and in vivo in a murine model have shown increased sensitivity of blastic plasmacytoid dendritic cells to tagraxofusp compared to other chemotherapeutic drugs.[@CIT0025]

Currently, tagraxofusp is the only targeted therapy with a prospective evaluation of safety and efficacy in BPDCN, in two clinical trials.[@CIT0026],[@CIT0027] The main results concerning efficacy are shown in [Table 1](#T0001){ref-type="table"}. Tagraxofusp, administered intravenously at a dose of 12 or 12.5 mg/kg/day for 5 days every 3 weeks, results in promising clinical activity in BPDCN, and in all the sites involved in the disease (skin, bone marrow, spleen, lymph node and viscera). More than half of the patients respond to the treatment. However, responses seem longer and more profound and the rate of complete response is higher in treatment-naive patients than in previously treated patients. Furthermore, it is an effective bridge to transplantation in front-line therapy. In the trial by Pemmaraju and colleagues, 45% of the patients treated with tagraxofusp in a first-line setting (12 µg/kg) were bridged to SCT during remission. Median overall survival (OS) was not reached in the group of treatment-naive patients, whereas median OS reached 8.5 months in previously treated patients, most of whom were not bridged to transplantation (one patient). Further studies are needed to assess the benefit of autologous or allogeneic stem cell transplantation after tagraxofusp.Table 1Efficacy and Safety Profile of Tagraxofusp in BPDCNReferencesNumber of PatientsMedian Age (Years)Prior TherapyDoseMedian Number of Cycles of TreatmentBest ResponsesMedian Time Before ResponseDuration of ResponseOverall SurvivalBPDCN-Related DeathTotal Rate of Grade\
≥3\
ToxicitiesRate of Main Grade ≥3 ToxicitiesRate of Treatment Interruptions or Lack of Completions for Toxic CausesRate of Treatment-Related DeathsFrankel et al, *Blood*, 2014[@CIT0026]11 (9 evaluable for objective response)70 (range, 40 to 77)None: n=4\
 \
Yes:\
n=712.5 mg/kg/day for 5 days\
 \
Possible second course on disease recurrence1 (1-2)Treatment-naive patients:\
- ORR: 100%\
- CR: 50%\
- PR: 50%\
Previously treated patients (2 non-evaluable):\
- ORR: 60%\
- CR: 60%-Treatment-naive patients:\
1 to 7 months\
 \
Previously treated patients:\
3 to 20 months-4 (36%)72%- Increase in transaminases: 36% (4/11)\
- Thrombocytopenia: 55% (6/11)\
- Neutropenia: 9% (1/11)\
- Hyponatremia: 9% (1/11)6 (55%)0Pemmaraju et al, *NEJM*, 2019[@CIT0027]4270 (range, 22 to 84)None: n=29\
 \
Yes: n=1312 mg/kg/day for 5 days,\
21-day cycles\
 Treatment-naive patients:\
5 (range, 1 to 43)\
 \
Previously treated patients:\
3 (range, 1 to 7)Treatment-naive patients:\
- ORR: 90%\
- CR: 72%\
- PR: 17%\
 \
Previously treated patients:\
- ORR: 69%\
- CR: 38%\
- PR: 31%Treatment-naive patients:\
43 days (range, 14 to 131)\
 \
Previously treated patients:\
24 days (range, 17 to 48)Treatment-naive patients:\
Median duration not reached after a median of 19 months of follow-up\
 \
 \
Previously treated patients:\
2.8 months (range, 0.7 to 14)Treatment-naive patients:\
- at 18 months: 59%\
- at 24 months: 52%\
 \
Previously treated patients:\
Median =\
8.5 monthsTreatment-naive patients:-\
 \
 \
Previously treated patients:-81%- Increase in transaminases: ALAT: 36%ASAT: 34%\
- Thrombocytopenia: 40%\
- Neutropenia: 11%\
- Febrile neutropenia: 9%\
- Anemia: 11%\
- Hyponatremia: 13%\
- Tumor lysis syndrome: 11%\
- Capillary leak syndrome: 6%-3 (7%)[^1][^2]

It is of note that the benefit of tagraxofusp seems persistent in patients over 70 years old, with overall response and CR rates of 100% and 70% respectively in treatment-naive patients, and 70% and 10% respectively in previously treated patients.

Toxicity Profile {#S0004-S2003}
----------------

The toxicity profile of tagraxofusp in clinical trials is indicated in [Table 1](#T0001){ref-type="table"}. Toxicities of grade 3 or higher are common and concerned 72 to 81% of the patients in prospective clinical trials.

Acute adverse events can occur during treatment or within a few hours after the infusion. They include chills, fever, nausea, and sometimes even hypoxemia and hypotension. These adverse events are mild to moderate in severity, transient, and easily manageable.

An increase in transaminases and thrombocytopenia are the most common grade ≥ 3 toxicities.

It must be emphasized that tumor lysis syndrome can occur.

Capillary leak syndrome (CLS) is a specific and frequent tagraxofusp toxicity. It occurs in 20% of patients, most frequently in the first week during the first treatment cycle. In most instances the severity is moderate and symptoms improve in a few days. However, severe or even lethal CLS has been reported after tagraxofusp. Since a decrease in serum albumin during the initial treatment days appeared to be the most consistent predictor of CLS, it should be strictly monitored. IV albumin supplementation is required to maintain serum albumin ≥ 3.2 g/dl before tagraxofusp administration, and tagraxofusp should be withheld until CLS signs have resolved. Consequently, severe undernutrition and heart failure can promote CLS and interfere with treatment.

Preliminary Results in Other Malignancies {#S0005}
=========================================

Tagraxofusp treatment is not specific to BPDCN. It has been tested in relapsed or refractory (R/R) CD123-expressing myeloproliferative neoplasms, including AML and myeloproliferative neoplasms (MPN) such as chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF). Related early-stage clinical trials are ongoing (NCT02268253, NCT02270463). Preliminary results have already been communicated.

In 18 R/R CMML patients, tagraxofusp showed 3 complete responses in bone marrow and 100% responses in spleen, including a 67% of reduction of ≥ 50%.[@CIT0028]

In 27 R/R MF patients, tagraxofusp treatment significantly decreased symptoms in 45% of the patients, and reduced spleen size in 53% of the 17 evaluable patients with baseline splenomegaly.[@CIT0029]

In both cases, the most frequent treatment-related adverse events were hypoalbuminemia (31 to 43%), thrombocytopenia (24 to 30%) and nausea (24 to 38%). The most frequent grade ≥3 adverse events were thrombocytopenia (8 to 13%) and anemia (14 to 17%). Capillary leak syndrome occurred in up to 19% of the patients, but the severity remained intermediate (grade 2).

Tagraxofusp has also been tested in other hematologic malignancies because of the high levels of CD123-expressing plasmacytoid dendritic cells (pDCs) in the tumoral micro-environment but not at the tumoral cell surface. For instance, tagraxofusp has been used in a Phase 1/2 trial in combination with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.[@CIT0030],[@CIT0031]

Furthermore, tagraxofusp treatment tends not to be restricted to cancers since it has recently been used to target CD123-expressing pDCs in patients with systemic sclerosis.[@CIT0032] These cells are known to promote the inflammation and disease pathogenesis observed in patients with systemic sclerosis and lupus.

Conclusion and Perspectives {#S0006}
===========================

Tagraxofusp is effective in treating BPDCN, especially as a front-line therapy. It has shown promising clinical activity, with a high overall response rate and prolonged responses, even in elderly patients who are unsuitable candidates for stem cell transplantation. It seems to improve survival, but comparative trials are needed to affirm this. Grade ≥ 3 adverse events are common. They are mainly represented by an increase in transaminases and thrombocytopenia. CLS can be severe and is an important adverse event to anticipate. As a result, tagraxofusp treatment requires preserved hepatic and cardiac functions, and strict monitoring of serum albumin.

Factors of a good response and prognostic factors after tagraxofusp treatment are unknown and should be defined. Similarly, the role of autologous and allogeneic stem cell transplantation after tagraxofusp should be specified.

No CNS involvement at diagnosis of BPDCN or at relapse was reported in patients treated with tagraxofusp. CNS involvement in BPDCN can occur in up 10% of patients. Therefore, the efficacy of tagraxofusp in treating or preventing this condition remains to be specifically assessed.

The efficacy of tagraxofusp in BPDCN may be increased in association with other cytotoxic drugs or targeted therapies. The high cost of the drug (26,660 US dollars/mL), and the absence of cost-effectiveness studies in real-world patients so far, highlights the need to develop a good biology-driven rationale to prescribe this drug in BPDCN and in other malignancies.
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[^1]: **Notes:** "-" means "unavailable data"; grades of adverse events are established according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

[^2]: **Abbreviations:** ORR, overall response rate; CR, complete response; PR, partial response; ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase.
